Psoriasis biosimilars and pricing changes herald treatment paradigm disruptions
Experts predict that physicians may favour emerging biosimilar versions of Stelara over more effective originator IL-23 drugs.
Experts predict that physicians may favour emerging biosimilar versions of Stelara over more effective originator IL-23 drugs.
What's Your Reaction?
